Investigational drug · Phase 2
GV20-0251
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "GV20-0251"
First trial start
2023
Mar 23, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GV20-0251", any sponsor or status.
Conditions studied
As listed on its trial records.
- Endometrial Carcinoma (EC)
- Squamous Head and Neck Carcinoma
- pMMR/MSS Adenocarcinoma of the Colon or Rectum
- Non-Small Cell Lung Cancer
- Uterine Cervical Neoplasms
- Triple Negative Breast Neoplasms
- Prostatic Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Esophageal Squamous Cell Carcinoma
- Cholangiocarcinoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Stomach and esophageal cancer · Head and neck cancer · Endometrial cancer · Oncology · Kidney and urology · Gastroenterology and liver · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "GV20-0251" as an intervention, largest first.
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)Not yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07307053 · 600 participants (planned) · Start Jan 1, 2026 · Primary completion Jan 31, 2029
Drug: BL-B01D1; VSV injection and 18 more · For: Rare Malignant Neoplasm; Advanced Solid Tumors; Metastatic Solid Tumors
GV20 TherapeuticsIndustry
NCT05669430 · 365 participants (planned) · Start Mar 23, 2023 · Primary completion Dec 15, 2026
Drug: GV20-0251; GV20-0251 and 2 more · For: Solid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC) and 4 more
Sites: Los Angeles, California; Denver, Colorado; New Haven, Connecticut · 13 sites in all
GV20 TherapeuticsIndustry
NCT07070518 · 350 participants (planned) · Start Jul 11, 2025 · Primary completion Jul 16, 2027
Drug: GV20-0251 · For: Solid Tumor Cancer; Adult Refractory Cancer; Endometrial Carcinoma (EC) and 6 more
Sites: Beijing, China; Shanghai, China · 3 sites in all
- A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.Not yet recruiting
GV20 TherapeuticsIndustry
NCT07623642 · 227 participants (planned) · Start Jun 2, 2026 · Primary completion Jun 15, 2028
Drug: GV20-0251; anti-PD-1 monoclonal antibodies · For: Uterine Cervical Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms and 8 more
Sites: Beijing, China; Harbin, China
West China HospitalAcademic, hospital or other
NCT07106827 · 10 participants (planned) · Start Sep 4, 2025 · Primary completion Jun 11, 2027
Drug: GV20-0251 · For: HCC - Hepatocellular Carcinoma; Cholangiocarcinoma; Melanoma and 5 more
Sites: Chengdu, China
West China HospitalAcademic, hospital or other
NCT07457281 · 9 participants (planned) · Start Apr 1, 2026 · Primary completion Apr 1, 2027
Drug: GV20-0251; Sintilimab · For: Head and Neck Squamous Cell Carcinoma HNSCC
Sites: Chengdu, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.